Loading...
•
Sep 30, 2021
Glaukos Q3 2021 Earnings Report
Glaukos' financial performance for the third quarter of 2021, marked by a 15% increase in net sales and significant growth in glaucoma and corneal health net sales, was announced.
Key Takeaways
Glaukos Corporation reported a 15% increase in net sales, reaching $74.7 million in Q3 2021. Glaucoma net sales were $58.5 million, and Corneal Health net sales were $16.2 million. The company's gross margin was approximately 79%, and its non-GAAP gross margin was approximately 87%. Net income was $6.2 million, or $0.13 per diluted share.
Net sales increased by 15% to $74.7 million in Q3 2021 compared to $64.8 million in Q3 2020.
Glaucoma net sales reached $58.5 million, while Corneal Health net sales amounted to $16.2 million in Q3 2021.
Gross margin was approximately 79%, and non-GAAP gross margin was approximately 87% in Q3 2021.
Operating expenses totaled $48.3 million, and non-GAAP operating expenses were $69.9 million in Q3 2021.
Glaukos
Glaukos
Glaukos Revenue by Segment
Revenue by Segment
Glaucoma Revenue
CapyFin.com Forward Guidance
The company expects 2021 net sales to be in the range of $285 million to $290 million.